Category Archives: Epigenetics

6.8.1 DNA Hypermethylation in Cancer

CpG hypermethylation in gene promoters is the best characterized epigenetic abnormality in human malignancies. A common paradigm in cancer epigenetics is hypermethylation of the CpG-rich promoter regions of tumor-suppressor genes, resulting in epigenetic silencing of these genes (14). Indeed, for some of the most important tumor suppressorssuch as the CDKN2A gene encoding the p16 cell cycle inhibitorpromoter hypermethylation can be the most common mechanism underlying their functional loss during tumor formation, with the corresponding genetic pathways for loss of function (deletion/mutation) being utilized less commonly (230). Hypermethylated promoter DNA is associated with virtually every type of human tumor, with each type of tumor having its own signature of methylated genes, such as the methylation of GSTP1 in prostate cancer, the von HippelLandau syndrome gene VHL in renal cancer, the mismatch repair gene MLH1 in colon and endometrial cancers, and sometimes BRCA1 in breast cancer (231236). In some of these examples, the same tumor-suppressor gene is mutated or methylated as alternative pathways in the same tumor type: loss-of-function mutations in MLH1 and VHL are found in the germlines of patients with hereditary colon and renal cancer, respectively, and these same genes are hypermethylated and silenced in sporadic tumors of the same histologic type (231,237).

While gain of DNA methylation is often discussed as a late event in tumor progression, CpG hypermethylation in specific sequences often occurs early in cancer formation, sometimes preceding tumorigenesis. Examples of early epigenetic aberrations can also be cited in other adult malignancies: in cigarette smokers, CDKN2A promoter methylation occurs in dysplastic bronchial epithelial cells prior to the formation of overt lung cancers (238), promoter hypermethylation of tumor suppressor genes is already detectable in the pre-malignant lesion Barrett esophagus (239,240). One of the best substantiated examples of a very early epigenetic lesion predisposing to subsequent tumor formation is the gain of methylation of the H19 DMR on the maternal allele, which leads to the loss of imprinting of IGF2 expression and can often be detected in non-neoplastic kidney cells both in BWS-associated and sporadic cases of the pediatric kidney cancer Wilms tumor (227).

DNA hypermethylation has attracted much attention as a biomarker for cancer detection and classification. To be clinically applicable, an ideal tumor biomarker must be specific for cancer, and readily detectable in clinical specimens obtained through minimally invasive procedures. DNA hypermethylation seems to fulfill these requirements and has been considered to be a promising biomarker. Examining the methylation of a subset of genes (GSTP1, APC, RASSF1, and MDR1) distinguished primary prostate cancer from benign prostate tissues with sensitivities and specificities of greater than 90% (241,242). DNA methylation alterations can be detected and used as biomarkers in feces for colorectal cancer, urine for bladder cancer screening, and sputum to predict the occurrence of lung cancer (243245). However, for reasons that are complex but partly financial, these types of tests largely remain at the research stage and have not yet been widely adopted in clinical practice.

View original post here:
Epigenetics - an overview | ScienceDirect Topics

By Alma Laney and Alison Bernstein

This post is the first in a series about transgenerational inheritance, epigenetics, and glyphosate that address questions raised by the publication of the paper, Assessment of Glyphosate Induced Epigenetic Transgenerational Inheritance of Pathologies and Sperm Epimutations: Generational Toxicology.

Transgenerational inheritance is the concept that traits can be passed on from parent to great-grandchildren. In the context of toxicology, this hypothesis can be described as ancestral environmental exposures to non-mutagenic agents can exert effects in unexposed descendants. If you imagine a person being exposed to some substance, their reproductive cells are exposed so their children are also exposed (intergenerational inheritance). If that person is a pregnant female, the reproductive cells of their offspring are exposed so the grandchildren are also exposed (multigenerational inheritance). Thus, true transgenerational inheritance can only be observed in the great-grandchildrens generation (transgenerational inheritance).

Transgenerational inheritance can occur through epigenetic, ecological, or cultural mechanisms (See Figure 1 of the linked paper below).

The focus of the paper under discussion is the epigenetic mechanisms through the germline, or transgenerational epigenetic inheritance. In any experiment of transgenerational inheritance, it is critical to use a careful study design to separate the epigenetic piece from the other mechanisms.

Epigenetics can be defined as: the processes and marks on or around the DNA processes that control the activity of the genome and can be mitotically and/or meiotically inherited. It encompasses a set of mechanisms that regulate gene expression and that can be inherited from cell to cell within an organism. Sometimes, if they occur in germline cells, these mechanisms may also be inherited from parent to offspring. Epigenetic mechanisms can also be sensitive to environmental inputs. Because they can be modified by the environment and may be inherited from parent to offspring, epigenetic mechanisms are a prime candidate for the mediating transgenerational inheritance.

Epigenetics generally refers to four mechanisms.

These four mechanisms do not exist in isolation. They form a network of interacting mechanisms that all work together to affect gene expression. For an overview on these mechanisms of epigenetics, please visit the Intro to Epigenetics series at Mommy, PhD.

Transgenerational epigenetic inheritance is well documented in plants and the commonly used model organisms, such as C. elegans (roundworms) and D. melanogaster (fruit flies). However, whether transgenerational inheritance occurs in mammals is still unclear.

The existence of transgenerational epigenetic inheritance remains unclear in mammals. There are a few reasons why this is hard to answer.

First, humans are complicated. When we have evidence of transgenerational inheritance of a trait in people, it is nearly impossible to separate the cultural and ecological effects from the epigenetic effects to definitively say if that inheritance occurs partly or exclusively through a biological mechanism. In humans, exposures are rarely isolated to the original generation only, making it extremely difficult to separate out true transgenerational effections. In addition, even when exposures are isolated, those exposures often produce differences that have their own effects. In the example of the Holocaust, it is difficult to separate the effects of trauma from living through the Holocaust on offspring from the effect of having a parent who lived through the Holocaust on offspring.

In order to determine if transgenerational inheritance occurs, scientists must stop the exposure in the original generation to isolate the exposure. While this can be done in model organisms in the lab, exposures are rarely isolated to a single generation in humans. Even when they are, the genetic, ecological and cultural confounders are so complex that it is extraordinarily difficult to conclusively identify transgenerational epigenetic inheritance in humans.

Second, experimental design is extremely complicated. We can use model organisms (such as mice or rats) to control for some of these factors to determine if transgenerational epigenetic inheritance occurs in mammals. However, when properly designed, these experiments are extremely complicated, expensive, and time-consuming, as described in A guide to designing germline-dependent epigenetic inheritance experiments in mammals. These experiments can be done, but at this point in time, very few studies are properly designed to actually be able to answer this question. We will discuss this in more detail below when we get to the methods of the paper under discussion.

Third, germline reprogramming clears (erases) many epigenetic marks twice during mammalian development. First, DNA methylation marks are cleared during germ-cell development. There is a second wave of demethylation following fertilization; the timing of this demethylation and the reestablishment of methylation patterns is different for maternal and paternal chromosomes. A subset of genes (mostly imprinted genes) do not undergo this second wave of demethylation and are more sensitive to environmental regulation. Thus, only a subset of the genome could be undergoing translational epigenetic inheritance. While research in the area is still evolving, it is clear that more of the genome than previously thought is protected from this second wave of demethylation. But transgenerational epigenetic inheritance seems unlikely to be a genome-wide phenomenon.

This 2018 state of the science report on transgenerational inheritance from the National Toxicology Program cites 21 papers from the lab that published the current glyphosate study. It summarizes the weaknesses of the existing evidence and underscores the need for well-designed studies.

In conclusion, a broad range of exposures and outcomes have been reported to support transgenerational inheritance of health effects. Over 80 different agents have been tested in a transgenerational experimental design; and this state of the science review collected and categorized the literature into a systematic evidence map for transgenerational inheritance by broad health effect categories, exposures, and evidence streams. This scoping review and evidence map identifies serious limitations in the available bodies of evidence to support a systematic review for reaching hazard conclusions or even rating certainty in the bodies of evidence under evidence to decision frameworks such as the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.

This report includes assessments of potential bias in the studies that do exist. The images below show a summary of their assessment of bias in animals studies (top) and specifically in animal studies of vinclozolin (bottom). The top panel shows that the probability of bias is probably high for many papers on many measures, with more than half of papers showing a definitely high risk of bias for confidence in the exposure characterization. The bottom panel shows the risk of bias from individual studies.

You can see from these images that much of the risk of bias seems to arise from the failure to report specific aspects of the methods and results. Nine of the fifteen papers listed in this panel are from the lab that performed the study in question. The areas identified as being of high risk for bias are also problematic in the current study as we will go through in detail below. This doesnt necessarily mean that the studies are flawed or the results are biased, but it does mean that the results cannot be accurately interpreted and it is not possible to determine if they are flawed or valid.

View the other parts of our series on transgenerational epigenetic inheritance:

Read this article:
Part 1: What is Transgenerational Epigenetic Inheritance? - Biofortified Blog

By Alison Bernstein and Alma Laney

The paper Assessment of Glyphosate Induced Epigenetic Transgenerational Inheritance of Pathologies and Sperm Epimutations: Generational Toxicology reported transgenerational epigenetic inheritance and increased disease rates after glyphosate exposure. Not surprisingly, the paper generated a lot of attention and discussion. Due to the focus on glyphosate by activist groups and recent lawsuits, weve taken an in-depth look at the state of the science on transgenerational epigenetic inheritance, the data in this paper, and the larger body of work from this lab.

Whether glyphosate exposure causes health problems through transgenerational epigenetic inheritance is an important research question. The original EPA reference dose is based on a transgenerational phenotype, even though this result has been determined to be spurious and unrelated to treatment since more extensive evaluations in subsequent reproduction studies conducted at much higher doses did not replicate the offspring effects (as explained in the draft human health assessment for glyphosate).

In this series, we address questions about transgenerational inheritance and epigenetics in general, and this glyphosate study in particular.

See original here:
Transgenerational Epigenetic Inheritance and Glyphosate - Biofortified Blog

Sameer Joshi Call: +912067274191Email: [emailprotected]Pune, January 9,2020

Premium Market Insights has announced the addition of the Epigenetics Market . The report focuses on global major leading industry players with information such as company profiles, product picture and specification.

The Epigenetics market is driven by the driving factor such as declining prices of sequencing, and is likely to drive the market in the coming years. The declining costs associated with different strategies and methods for sequencing supports to influence the scale and scope of almost all genomic research projects. In 2000, cost for sequencing was US$ 3.7 billion, which dropped down to US$ 10 million in 2006 and declined to US$ 5,000 in 2012. Owing to factors such as advances in the field of genomics, development in different methods and strategies for sequencing, there is a notable decline in the cost of sequencing, that upsurge the growth of the market.The market is likely to restrain its growth due to the factors such as high cost of advanced technologies. Companies such as Illumina and PacBio offer instruments with high cost. For instance, Illumina MiSeq cost for US$ 128,000 and PacBio RS cost for US$ 695,000. Thus, the high cost of next generation sequencers is hindering the growth of the market for in the future. Whereas the use of the neuroepigenetics to diagnose the neurodevelopmental disorders is likely to contribute a potential market growth in the forecast period.

The Epigenetics market as per the product the segment is segmented as reagents, kits, enzymes, instruments and consumables and bioinformatics tools. The market of kits has the highest market share in 2017, contributing a market share of 29.8% and is expected to retain its dominance during the forecast period from 2018 to 2025. The epigenetic kits allows researchers to perform experiments, researchers to analyze epigenetic modifications efficiently and reliably by using antibodies directed against epitope tags or RNA-binding proteins. Thus holding the major market share. Likewise the reagents contributed 26.2% of the market share in the year 2017 and is expected to be the fastest growing market in the coming near future.

Get Sample PDF For More Professional And Technical Insights at:

https://www.premiummarketinsights.com/sample/TIP00000986

The Technology segment of the epigenetics market includes histone modification, DNA methylation and other technologies. The DNA methylation segment for the epigenetics market was valued at US$ 506.29 Mn in 2017 and is estimated to grow at a CAGR of 13.9% during the forecast period from 2017 to 2025, to reach US$ 1,361.67.0 Mn by 2025. The DNA methylation segments is likely to dominate the market in the coming future as it supports the development of therapies for diseases including cancer, lupus, muscular dystrophy and various congenital defects. Thus the DNA methylation segment is expected to hold major share and is also the fastest growing segment during the forecast period.

Some of the major primary and secondary sources included in the report epigenetics market are National Institute of Environmental Health Sciences (NIEHS), Epidemiology and Genomics Research Program (EGRP), Canadian Institutes of Health Research (CIHR), Synthetic Biology Leadership Council, Chinese Academy of Sciences, World Health Organization, European Union, Food and Drug Administration and more.

Get Complete Report at: https://www.premiummarketinsights.com/reports-tip/epigenetics-market

Contact Info:Name: Sameer JoshiEmail:[emailprotected]Organization: Premium Market InsightsPhone: +1-646-491-9876

About Premium Market Insights:

Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider.

Read the original here:
Epigenetics Market Expected to Reach US$ 2,611.57 Mn By 2025 - Merck, Thermo Fisher, Abcam, Agilent, Active Motif, QIAGEN, Bio-Rad, PerkinElmer, New...

As I reflect on my childhood, knowing what I know regarding Adverse Childhood Experiences or ACEs, and my score of a three, along with a high school graduating ACT score of a 15, it would seem unusual that in my freshman year at Northern State University that I, a probationary student would end the year on the Deans Presidential Scholarship List with a 4.0 GPA.

Equally astounding, was my completion of a Master of Science in Pastoral Care and Counseling degree with a 3.9 GPA. My life goal was to become an educator to make learning enjoyable and to be kind to others in the process. A defining moment in my life was when the well-intentioned high school counselor took me aside, and gently said, You might be able to be a teachers assistant, although because of your test score, not the actual classroom teacher.

It was exactly what I needed to hear. It agitated me just enough to set my sight on my goal and nothing was going to stop me from achieving it. I graduated from the university with an elementary education degree and a special education degree (K-12).

I went on to enjoy 27 delightful years as a classroom teacher until I had the opportunity to join St. Francis Health. Now in my seventh year, this life-giving Mission and Ministry position continues to exemplify how my students and parents continue to be my best teachers.

University of Pennsylvania Psychologist, Angela Duckworth, would call this grit. She defines grit as the perseverance and passion for long term goals with no particular concern for rewards or recognition along the way. It combines resilience, ambition, and self-control in pursuit of goals that take months, years, or even decades. Her published research in the book, Grit-The Power of Passion and Perseverance, a New York Times bestseller documents how grit predicts long-term success in nearly every realm of life.

Dr. Duckworths studies began when she was teaching math to seventh graders. She realized IQ wasnt the only factor separating successful students from those who struggled. Goals through time were the highly predictive of success. In most research studies, grit and measures of talent and IQ are unrelated, suggesting that talent puts no limits on capacity for passion and perseverance.

Since we can only teach what we truly know, below is Dr. Duckworths Pulse Check to gauge your current level of grit, considering how true the following are for you:

1. I enjoy projects that take years to complete.

2. I am working towards a very long-term goal.

3. What I do each day is connected to my deepest personal values.

4. There is at least one subject or activity that I never get bored of thinking about.

5. Setbacks dont discourage me for long.

7. I finish whatever I begin.

8. I never stop working to improve.

Your disposition to pursue long-term goals with passion and perseverance like risk for heart disease, interest in art, and your intelligence is both heritable and malleable. Ninety-nine percent of your genes are the same as mine or your neighbors and literally everyone else you know. Only a tiny fraction of human genes differ. These genetic differences among people are correlated with differences in our physical and psychological characteristics.

Our genetic heritage does not have complete authority over our life destiny UNLESS we allow it. From Harvard University Center on the Developing Child epigenetics research, we know that genes make a difference AND so does experience so dont assume that nature and nurture are mutually exclusive. It also reminds us of how essential it is to look for ways to enrich the environments of the young people in our lives. Epigenetics refers to changes in which genes are expressed and how early experiences alter gene expression and shape development.

According to Dr. Ducksworths research, here are some ways to encourage grit in others:

1. Model it. If you love what you do, let others know. Wear your passion on your sleeve. When you fail, openly share your frustration yet go out of your way to point our what you learned from the experience. Emphasize playing the long game in life. Life is a marathon, rather than a sprint.

2. Celebrate it. When you see grit, draw attention to it. Your work on this project has demonstrated tremendous perseverance. I know it took a huge effort on your part. Praise passion such as: You are really in the flow with this project and Im so happy for you.

3. Enable it. The paradox of grit is that determination of individuals is made possible by warmth and support of friends, families whether biological or chosen, teachers, and mentors.

God honors a beautiful blend of gift and grit! He gives the gift and expects us to have the grit to practice and learn how to use it effectively. ~ Beth Moore

For more information on how to most effectively use behavioral science to transform peoples lives to bring out their highest good go to: bcfg.wharton.upenn.edu Creating Enduring Behavior Change or Dr. Duckworths: Characterlab.org for actionable advice for parents and teachers based on science.

Sandy Block-Hansen, MS. St. Francis Healthcare Campus Family Footprints Coordinator. A Catholic Health Initiative Mission and Ministry program created to support, inform, and offer resources to parents in the role of parenting. She can be reached at sandrablock-hansen@catholichealth.net or 218.643.0475

See the original post:
Grit is the glue in life's marathon! | Health - Wahpeton Daily News

In this Epigenetics Market Global Industry Analysis & Forecast to 2030 research report, the central factors driving the advancement of this industry were recorded and the business accessories and end overseers were indulgent. This statistical surveying Epigenetics report investigates and inspects the industry and determines a widely inclusive estimate of its development and its details. Another perspective that was efficient is the cost analysis of the prime products driving in the Epigenetics Industry remembering the overall revenue of the manufacturers.

The following key Epigenetics Market insights and pointers are covered during this report:

Request a demo sample: https://prophecymarketinsights.com/market_insight/Insight/request-sample/36

The prime manufacturers covered during this report are:

Illumina Inc., Thermo Fisher Scientific Inc., Merck Millipore Limited, Bio-Rad Laboratories, Inc., Qiagen Inc., Zymo Research Corporation, Diagenode s. a., Enzo Life Sciences, Inc. and New England Biolabs Inc.

Detail Segmentation:

Download PDF Brochure @ https://prophecymarketinsights.com/market_insight/Insight/request-sample/36

The report is an entire guide in providing complete Epigenetics processes, cost structures, raw materials, investment feasibility, and investment return analysis. The SWOT analysis, market growth, production, profit, and supply-demand statistics are offered

The historical and future trends, prices, product demand, prospects, and Epigenetics marketing channels are stated. The current business and progressions, future methodologies, market entrants are explained. The consumers, distributors, manufacturers, traders, and dealers in Business Intelligence (Bi) Software Market are covered. A comprehensive research methodology, market size estimation, market breakdown, and data triangulation is roofed.

Checkout Complete Details Here: https://prophecymarketinsights.com/market_insight/Global-Epigenetics-Market-By-Product-36

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

Browse Similar Reports:

https://instanews247.com/world-deferiprone-market-size-share-growth-survey-2020-to-2030-and-industry-analysis-report/

https://instanews247.com/porcine-reproductive-respiratory-syndrome-vaccines-market-research-report-2020-2030-demand-growth-opportunities-2030/

https://instanews247.com/porcine-vaccines-market-revenue-opportunity-segment-and-key-trends-2020-2030/

Read the original:
Global Epigenetics Market Perspective with Study of Leading Players and Revenue to Significant Growth Forecast by 2030 - Citi Blog News

MADRID, Spain and CAMBRIDGE, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces that its management will present recent progress of vafidemstat in central nervous system (CNS) indications at the 3rd Neuroscience Innovation Forum in San Francisco on January 12.

Vafidemstat is in Phase II clinical development in multiple trials. It has demonstrated promise as a safe, well-tolerated and differentiated therapeutic option for treating agitation and aggression, and for treating non-aggressive features of three distinct psychiatric diseases.

Oryzons CEO Dr. Carlos Buesa and CMO Dr. Roger Bullock will make the presentation at the Marines' Memorial Club, a day before the JP Morgan Healthcare Conference. Oryzons presentation will take place at 13:50 PT in Track E in the Room Commandants. At the same event, Dr. Buesa will also participate in the Advances in Alzheimers & Other Cognitive Disorders Panel discussion at 9:30 am PT.

Oryzon will also take part in the 9th Annual LifeSci Advisors Corporate Access Event from January 13 to January 15, 2020 where Oryzons CEO and other management will hold meetings with pharmaceutical companies, institutional investors, analysts and other members of the biotech community at the Sir Francis Drake Hotel (450 Powell Street).

About OryzonFounded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzons LSD1 program has rendered two compounds, vafidemstat and iadademstat, in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon has offices in Spain and the United States. For more information, visit http://www.oryzon.com.

About VafidemstatVafidemstat (ORY-2001) is an oral, CNS optimized LSD1 inhibitor. The molecule acts on several levels: it reduces cognitive impairment, including memory loss and neuroinflammation, and at the same time has neuroprotective effects. In animal studies vafidemstat not only restores memory but reduces the exacerbated aggressiveness of SAMP8 mice, a model for accelerated aging and Alzheimers disease (AD), to normal levels and also reduces social avoidance and enhances sociability in murine models. In addition, vafidemstat exhibits fast, strong and durable efficacy in several preclinical models of multiple sclerosis (MS). Oryzon has performed a Phase IIa clinical trial in aggressiveness in patients with different psychiatric disorders (REIMAGINE), with positive preliminary clinical results reported. Additional Phase IIa clinical trials with vafidemstat are ongoing in patients with Mild to Moderate AD (ETHERAL), in aggressiveness in patients with moderate or severe AD (REIMAGINE-AD), and in Relapse-Remitting and Secondary Progressive MS (SATEEN).

About IadademstatIadademstat (ORY-1001) is a small oral molecule, which acts as a highly selective inhibitor of the epigenetic enzyme LSD1 and has a powerful differentiating effect in hematologic cancers (See Maes et al., Cancer Cell 2018 Mar 12; 33 (3): 495-511.e12.doi: 10.1016 / j.ccell.2018.02.002.). A first Phase I/IIa clinical trial with iadademstat in refractory and relapsed acute leukemia patients demonstrated the safety and good tolerability of the drug and preliminary signs of antileukemic activity, including a CRi. Beyond hematological cancers, the inhibition of LSD1 has been proposed as a valid therapeutic approach in some solid tumors such as small cell lung cancer (SCLC), medulloblastoma and others. Oryzon is currently conducting two Phase IIa clinical trials of iadademstat in combination; the first one in combination with azacitidine in elderly AML patients (ALICE study) and the second one in combination with platinum/etoposide in second line SCLC patients (CLEPSIDRA study). In both studies, preliminary clinical results have been reported.

Story continues

FORWARD-LOOKING STATEMENTS This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words expects, anticipates, believes, intends, estimates and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisin Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forwardlooking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States or any other jurisdiction. Oryzons securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of Oryzons securities to be made in the United States will be made by means of a prospectus that may be obtained from Oryzon or the selling security holder, as applicable, that will contain detailed information about Oryzon and management, as well as financial statements.

See the original post here:
ORYZON to Present at the 3rd Neuroscience Innovation Forum in San Francisco - Yahoo Finance

HOUSTON, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers,today announced that it will host a key opinion leader (KOL) call on Epigenetics, Thursday, December 19th at 12pm Eastern Time.

The call will feature a presentation by KOLs Damon Reed, MD, Moffitt Cancer Center, and Johnathan Whetstine, PhD, Fox Chase Cancer Center, who will discuss Epigenetics, and how drugs that regulate gene expression (epigenetic drugs) are a viable strategy for treatment and management of cancer. They will also discuss recent clinical successes with epigenetic drugs, and what to expect from novel agents. Drs. Reed and Whetstine will be available to answer questions at the conclusion of the call.

The call will also feature a presentation by Salarius management team, which will provide an update on their lead program, Seclidemstat. Management will share the latest on their clinical program and on new areas of interest including immunotherapy and select tumor mutations. Seclidemstat, a reversible LSD1 inhibitor, inhibits LSD1s enzymatic and scaffolding properties, representing a viable therapeutic option for patients who need it the most.

Damon Reed, MD is the Director of the Adolescent and Young Adult Program at Moffitt Cancer Center, an Associate Member of the Sarcoma Department at Moffitt Cancer Center and an Assistant Professor of Pediatrics at the University of South Florida. He is also on staff as a specialty physician at All Childrens Hospital in St. Petersburg, FL. He is the Leader of the National Pediatric Cancer Foundations pediatric phase I consortium, the Sunshine Project. Dr. Reeds research interests include chemotherapeutic approaches to sarcoma in the pediatric and adolescent and young adult population. He is interested in establishing relevant preclinical sarcoma models, establishing and testing biomarkers for targeted therapies and translating predictive testing and combinations of agents towards personalized medicine in sarcoma and other rare cancers. A graduate of Case Western Reserve University School of Medicine in Cleveland, OH, Dr. Reed served a combined pediatric residency program at Boston Childrens Hospital-Harvard Medical School and Boston Medical Center-Boston University School of Medicine. He completed his fellowship training in pediatric hematology/oncology at St. Jude Childrens Research Hospital. Dr. Reed has received numerous academic awards, including graduating valedictorian from Canfield High School and summa cum laude from the University of Dayton. He received the CWRU Medical Alumni Association Board of Trustees Award for Outstanding Service and Contributions to the School of Medicine and was named to the Alpha Omega Alpha Honor Medical Society. Dr. Reed is a member of several professional associations, including the American Association for Cancer Research, Connective Tissue Oncology Society and American Society of Clinical Oncology. Dr. Reed is the Principal Investigator of Salariuss ongoing Ewing sarcoma Phase 1/2 clinical trial.

Johnathan Whetstine, PhD is the Program Leader of the Cancer Epigenetic Program at the Fox Chase Cancer Center. A rising star in the field of epigenetics, Dr. Whetstine has made groundbreaking discoveries that have expanded the field and provided significant implications for understanding tumor heterogeneity and drug response. In recognition of the promise of his research, he holds the prestigious Scholar award from the Leukemia & Lymphoma Society and a National Institutes of Health R01 grant, as well as funding from the American Lung Association, Alex Lemonade Stand Foundation and AstraZeneca. Recently, Dr. Whetstine helped coordinate the Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic, which brought together experts in the field of LSD1 research. Prior to Fox Chase, Dr. Whetstine was at Massachusetts General Hospital Cancer Center and Harvard Medical School in Boston, where he served as vice chair of the Epigenetics Program. He also held appointments as associate geneticist and associate professor in the department of medicine, respectively. He completed his postdoctoral fellowship in epigenetics/pathology in the laboratory of Yang Shi, PhD, at Harvard Medical School, and earned his PhD in pharmacology from Wayne State University in Detroit. Dr. Whetstine has served on Salariuss Advisory Board.

About Salarius Pharmaceuticals Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company targeting the epigenetic causes of cancers and is developing treatments for patients that need them the most. Epigenetics refers to the regulatory system that affects gene expression. In some cancers, epigenetic regulators often become dysregulated and incorrectly turn genes on or off leading to cancer progression. Drugs that can safely modify the activity of these epigenetic regulators may correct the gene changes that are driving the disease. The companys lead candidate, Seclidemstat, is currently in clinical development for treating Ewing sarcoma, for which it has Orphan Drug designation and Rare Pediatric Disease Designation by the U.S. Food and Drug Administration. Salarius believes that Seclidemstat is one of only two reversible inhibitors of the epigenetic modulator LSD1 currently in human trials, and that it could have potential for improved safety and efficacy compared to other LSD1-targeted therapies. Salarius is also developing Seclidemstat for several cancers with high unmet medical need, with a second Phase 1 clinical study in advanced solid tumors, including prostate, breast and ovarian cancers. Salarius receives financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and is also the recipient of an $18.7 million Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit salariuspharma.com.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements may be identified by terms such as will, can, could, believe, feel, plan, allow, will, expect, provide, able to, position, anticipate, progress, potential, target, and similar terms or expressions or the negative thereof. Examples of such statements include, but are not limited to, statements regarding: the companys lead program, Seclidemstat, the companys clinical program and new areas of interest including immunotherapy and select tumor mutations; the potential for Seclidemstat as viable therapeutic option for patients who need it the most; the companys belief that Seclidemstat is one of only two reversible inhibitors of the epigenetic modulator LSD1 currently in human trials, and that it could have potential for improved safety and efficacy compared to other LSD1-targeted therapies; and the companys development of Seclidemstat for several cancers with high unmet medical need, with a second Phase 1 clinical study in advanced solid tumors, including prostate, breast and ovarian cancers. Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements are subject to risks and uncertainties which could cause actual results and performance to differ materially from those discussed in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: the ability of the company to raise additional capital to meet the companys business operational needs and to achieve its business objectives and strategy; the companys ability to project future capital needs and cash utilization; available sources of cash, including from CPRIT and its equity line; future clinical trial results; that the results of studies and clinical trials may not be predictive of future clinical trial results; the sufficiency of Salarius intellectual property protection; risks related to the drug development and the regulatory approval process; the competitive landscape and other industry-related risks; market conditions which may impact the ability of Salarius access capital under its equity line; the possibility of unexpected expenses or other uses of Salarius cash resources; and other risks described in Salarius filings with the Securities and Exchange Commission, including those under the heading Risk Factors. The forward-looking statements contained in this press release speak only as of the date of this press release and are based on managements assumptions and estimates as of such date. Salarius disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.

ContactsInvestor Relations LifeSci Advisors, LLCJeremy FefferManaging Director(212) 915-2568 jeremy@lifesciadvisors.com

Media Relations:Tiberend Strategic Advisors, Inc.Johanna BennettSenior Vice President(212) 375-2686jbennett@tiberend.com

More:
Salarius Pharmaceuticals Hosting Key Opinion Leader Call on Epigenetics, The Regulatory System That Affects Gene Expression - BioSpace

One out of eight couples has trouble conceiving, with nearly a quarter of those cases caused by unexplained male infertility. For the past decade, research has linked that infertility to defective sperm that fail to evict proteins called histones from DNA during development. However, the mechanisms behind that eviction and where this is happening in the sperm DNA has remained both controversial and unclear.

Now, researchers atPenn Medicineshow, using newer genome-wide DNA sequencing tools, the precise genetic locations of those retained histones, as well as a key gene regulating it. The findings were published inDevelopmental Cell.

Taking it a step further, the researchers created a new mouse model with a mutated version of the gene,Gcn5, which allows investigators to closely track the defects in sperm from the early stages of sperm development through fertilization and on. This is an important step forward as it could lead to a better understanding of not only infertility in menand ways to potentially reverse itbut also the suspected epigenetic mutations being passed onto the embryo from males either naturally or through in vitro fertilization.

Epigenetics, the factors influencing an organisms genetics that are not encoded in the DNA, play a strong role in sperm and egg formation.

For men who have unexplained infertility, everything may look normal at the doctors: normal semen counts, normal motility. Yet they can still have problems conceiving, says first authorLacey J. Luense, a research associate in the lab of the study's senior author,Shelley L. Berger, the Daniel S. Och University Professor in the departments of Cell and Developmental Biology in the Perelman School of Medicine and Biology in the School of Arts and Sciences, and director of the Penn Epigenetics Institute. One explanation for persistent problems is histones being in the wrong location, which may affect sperm and then early development. Now, we have a really good model to study what happens when you dont get rid of the histones appropriately in the sperm and what that may look like in the embryo.

Read more at Penn Medicine News.

Originally posted here:
Uncovering a defective sperm epigenome that leads to male infertility - Penn: Office of University Communications

In a recent study published by Prophecy Market Insights, titled, Global Epigenetics Market Research Report, analysts offers an in-depth analysis of global Epigenetics market. The study analyses the various aspect of the market by studying its historic and forecast data. The research report provides Porters five force model, SWOT analysis, and PESTEL analysis of the Epigenetics market. The different areas covered in the report are Epigenetics market size, drivers and restrains, segment analysis, geographic outlook, major manufacturers in the market, and competitive landscape.

Key Players of Epigenetics Market:

Illumina Inc., Thermo Fisher Scientific Inc., Merck Millipore Limited, Bio-Rad Laboratories, Inc., Qiagen Inc., Zymo Research Corporation, Diagenode s. a., Enzo Life Sciences, Inc. and New England Biolabs Inc.

Download Sample Copy of This Report @ https://prophecymarketinsights.com/market_insight/Insight/request-sample/36

The research report, Epigenetics Market presents an unbiased approach at understanding the market trends and dynamics. Analysts have studied the historical data pertaining to the market and compared it to the current market trends to paint an object picture of the markets trajectory. The report includes SWOT analysis and Porters five forces analysis to give the readers an in-depth assessment of the various factors likely to drive and restrain the overall market.

Market Segmentation:

Request PDF catalogue for this report @ https://prophecymarketinsights.com/market_insight/Insight/request-sample/36

Table of Contents

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the global Epigenetics market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company: Here, the competition in the global Epigenetics market is analyzed, taking into consideration price, revenue, sales, and market share by company, market concentration rate, competitive situations and trends, expansion, merger and acquisition, and market shares of top 5 and 10 companies.

Company Profiles and Sales Data: As the name suggests, this section gives the sales data of key players of the global Epigenetics market as well as some useful information on their business. It talks about the gross margin, price, revenue, products and their specifications, applications, competitors, manufacturing base, and the main business of players operating in the global Epigenetics market.

Market Status and Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Epigenetics market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User: This part of the research study shows how different application segments contribute to the global Epigenetics market.

Market Forecast: Here, the report offers complete forecast of the global Epigenetics market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Upstream Raw Materials: The report provides analysis of key raw materials used in the global Epigenetics market, manufacturing cost structure, and the industrial chain.

Marketing Strategy Analysis and Distributors: This section offers analysis of marketing channel development trends, indirect marketing, and direct marketing followed by a broad discussion on distributors and downstream customers in the global Epigenetics market.

Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

Appendix: Here, we have provided a disclaimer, our data sources, data triangulation, market breakdown, research programs and design, and our research approach.

For More Info: https://prophecymarketinsights.com/market_insight/Global-Epigenetics-Market-By-Product-36

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

Browse Similar Reports:

https://cryptonewsgazette.com/carbon-black-market-assessment-on-competition-2020-2030/

https://cryptonewsgazette.com/activated-carbon-market-to-reap-excessive-revenues-by-2020-2030/

https://cryptonewsgazette.com/iron-powder-market-evolving-latest-trends-to-lead-global-industry-by-2020-2030/

This post was originally published on Info Street Wire

Read the original:
Epigenetics Market: 2020 Industry Outlook, Comprehensive Insights, Growth and Forecast 2030 - Info Street Wire